Clinical Trials on Protein Supplementation in New Zealand

Total 1063 results

Cardinal Tien Hospital

Completed

The Impact of Exercise Intervention on Physical Function Falls, and Physical Restraint for Long-term Care Residents

Protein Supplementation | Exercise Intervention

Taiwan
University of Auckland, New Zealand
Singapore Institute for Clinical Sciences; Massey University; AgResearch; The Riddet...

Completed

Acute Meat and Alternative Intake (PRotEin DIet SatisfacTION Trial 3) (PREDITION)

Diet, Healthy | Protein; Disease

New Zealand
Society for Applied Studies
World Health Organization

Completed

Efficacy of Newborn Vitamin A Supplementation Versus Placebo in Improving Child Survival (NeoVitA Trial)

Neonatal Vitamin A Supplementation

India
Novartis Pharmaceuticals

Terminated

An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function

Histologically-proven and Radiologically-confirmed Solid Tumors

Italy, New Zealand
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, New Zealand
Pfizer

Terminated

Study Evaluating The Safety Of Xyntha In Usual Care Settings

Hemophilia A

United States, New Zealand
Winthrop University Hospital

Completed

Recruiting All Strictly Breast-fed Babies With Blood In Stool

Breast Milk Protein Intolerance

United States
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Hemophilia A

Spain, Canada, United States, New Zealand, Italy, Poland
Wyeth is now a wholly owned subsidiary of Pfizer

Withdrawn

Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A

Hemophilia A

Italy, United States, Netherlands, United Kingdom, Germany, New Zealand, Belgium, France
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale (Elevate)

Severe Hemophilia A

United States, Australia, New Zealand
Catalyst Biosciences

Completed

Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia

Hemophilia A

United States, Belgium, Hungary, Italy, New Zealand, South Africa, Turkey, United Kingdom
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery

Hemophilia A

United States, New Zealand, Australia, Hungary, Sweden, Austria, Poland, Romania
Bayer

Terminated

Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors

Hemophilia A and B

Australia, United Kingdom, Taiwan, Japan, Korea, Republic of, Austria, Bulgaria, Hungary, Italy, France, New Zealand
Taipei Medical University Shuang Ho Hospital

Completed

Tamoxifen Treatment in Patients With Motor Neuron Disease

Amyotrophic Lateral Sclerosis | ALS Functional Ration Scale | TAR-DNA-binding Protein-43 | Tamoxifen | mTOR

Taiwan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A

Hemophilia A

Poland, Belgium, France, Italy, Spain, United States, Australia, Netherlands, New Zealand, Sweden, Germany, Finland, Hungary
ONY

Suspended

Administration of Surfactant Through an Instillation Device Infasurf® (Calfactant) in Neonates- A Pilot Study

Chronic Lung Disease | RDS of Prematurity | Surfactant Protein B Deficiency

United States
George A. Kaysen, M.D.
Beth Israel Medical Center

Terminated

The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients (ICM)

Hypoalbuminemia

United States
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)

Multiple Myeloma

Belgium, Korea, Republic of, Denmark, United Kingdom, Australia, New Zealand, Italy, Spain, France
Green Cross Corporation
Atlantic Research Group

Unknown

Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A

Hemophilia A

United States, Canada, New Zealand, Poland, Russian Federation, Ukraine, United Kingdom
Baxalta now part of Shire

Completed

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

Hemophilia A | Hemophilia B | Hemophilia A or B With Inhibitors

Poland, United States, Bulgaria, Romania, Japan, Russian Federation, New Zealand, Croatia, Ukraine, Brazil
Columbia University
Grifols Therapeutics LLC

Completed

Intravenous Immunoglobulin (IVIG) in Lung Transplantation

Lung Transplantation | Hypogammaglobulinemia

United States
Hoffmann-La Roche

Recruiting

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Korea, Republic of, Denmark, Spain, Australia, Italy, New Zealand, France, Canada
Memorial Sloan Kettering Cancer Center

Completed

Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation

Multiple Myeloma

United States
Far Eastern Memorial Hospital
Gynecologic Oncology Group

Recruiting

The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer

Vulvar Cancer, G9a Protein

Taiwan
Cogent Biosciences, Inc.

Terminated

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

Solid Tumor | HER-2 Protein Overexpression

United States
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B (PUPs B-LONG)

Hemophilia B

United States, Italy, Ireland, New Zealand, United Kingdom, Australia, Netherlands, Denmark, Poland, Sweden, France
Columbia University
Genzyme, a Sanofi Company

Recruiting

Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance

Monoclonal Gammopathy

United States
Skidmore College

Active, not recruiting

Daily Protein Pacing Effects on HbA1c in Type 2 Diabetics

Type 2 Diabetes | Protein Intake | HbA1c

United States
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors (HAVEN 1)

Hemophilia A

Korea, Republic of, United States, France, Germany, Italy, South Africa, Spain, Japan, United Kingdom, Poland, Taiwan, Australia, Costa Rica, New Zealand
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University; State University of New York -... and other collaborators

Active, not recruiting

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
Green Cross Corporation
Atlantic Research Group

Unknown

Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A

Hemophilia A

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Recruiting

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

Plasma Cell Myeloma

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery

Hemophilia A

United States
Baxalta now part of Shire
American Thrombosis and Hemostasis Network; UDC Rare Bleeding and Clotting...

Completed

Ceprotin Treatment Registry

Protein C Deficiency

United States, United Kingdom, Germany, Italy, Netherlands, Austria
Pfizer

Completed

Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII

Hemophilia A

United States, Argentina, Austria, Colombia, Croatia, Jordan, Mexico, New Zealand, Oman, Peru, Poland, Romania, Turkey
Icahn School of Medicine at Mount Sinai
Memorial Sloan Kettering Cancer Center; Hackensack Meridian Health

Completed

Treating Cancer-Related Fatigue Through Systematic Light Exposure (Light for Fatigue Study)

Fatigue | Multiple Myeloma

United States
Regeneron Pharmaceuticals

Recruiting

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment (LINKER-MM4)

Multiple Myeloma

United States, France
Pfizer
Bristol-Myers Squibb

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Multiple Myeloma

United States, Canada
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Recruiting

Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer

Gastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditions

United States
Geron Corporation

Completed

Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma

Multiple Myeloma

United States
Infinity Pharmaceuticals, Inc.

Completed

Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma (IPi-504-01)

Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center
National Institutes of Health (NIH)

Recruiting

Testing a New Imaging Agent to Identify Cancer

HER2-positive Metastatic Breast Cancer | HER-2 Protein Overexpression | HER-2 Positive Malignant Carcinoma of Breast

United States
Ochsner Health System
Boston Scientific Corporation

Recruiting

90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia (REALM)

Carcinoma, Hepatocellular

United States
Immune Control

Completed

Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant

Multiple Myeloma

United States
Weill Medical College of Cornell University
Onyx Therapeutics, Inc.

Active, not recruiting

Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma (CarBiRD)

Multiple Myeloma

United States
Weill Medical College of Cornell University
Celgene

Active, not recruiting

Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study

Multiple Myeloma

United States
Icahn School of Medicine at Mount Sinai
Bristol-Myers Squibb; Multiple Myeloma Research Consortium

Enrolling by invitation

A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma (CC-220)

Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center

Completed

Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center

Completed

Acupuncture for Symptom Control in Hematopoietic Stem Cell Transplantation Patients

Multiple Myeloma

United States

Clinical Trials on Protein Supplementation in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations